Ryan E T, Butterton J R, Zhang T, Baker M A, Stanley S L, Calderwood S B
Infectious Disease Unit, Massachusetts General Hospital, Boston 02114, USA.
Infect Immun. 1997 Aug;65(8):3118-25. doi: 10.1128/iai.65.8.3118-3125.1997.
Entamoeba histolytica is a significant cause of morbidity and mortality worldwide. The serine-rich E. histolytica protein (SREHP) is a surface-expressed trophozoite protein that includes multiple hydrophilic tandem repeats. A purified fusion protein between the dodecapeptide repeat of SREHP and cholera toxin B subunit (CTB) has previously been shown to be immunogenic in mice after oral inoculation when cholera toxin is coadministered as an immunoadjuvant. We engineered a live attenuated El Tor Vibrio cholerae vaccine strain, Peru2, to express the SREHP-12-CTB fusion protein to the supernatant from either a plasmid [Peru2 (pETR5.1)] or from a chromosomal insertion (ETR3). Vector strains were administered orally to germfree mice that were subsequently housed under nongermfree conditions; mice received one (day 0) or two (days 0 and 14) inoculations. No immunoadjuvant or cholera holotoxin was administered. Mice that received two inoculations of Peru2(pETR5.1) had the most pronounced antiamebic systemic and mucosal immunologic responses. Less marked, but significant, anti-SREHP serum immunoglobulin G antibody responses were also induced in mice that received either one or two oral inoculations of strain ETR3. Anti-V. cholerae responses were also induced, as measured by the induction of serum vibriocidal antibodies and by serum and mucosal anti-CTB antibody responses. These results suggest that V. cholerae vector strains can be successful delivery vehicles for the SREHP-12-CTB fusion protein, to induce mucosal and systemic antiamebic and anti-V. cholerae immune responses. The magnitude of these responses is proportional to the amount of SREHP-12-CTB produced by the vector strain.
溶组织内阿米巴是全球发病和死亡的一个重要原因。富含丝氨酸的溶组织内阿米巴蛋白(SREHP)是一种表面表达的滋养体蛋白,包含多个亲水性串联重复序列。先前已表明,当将霍乱毒素作为免疫佐剂共同给药时,SREHP的十二肽重复序列与霍乱毒素B亚基(CTB)之间的纯化融合蛋白经口服接种后在小鼠中具有免疫原性。我们构建了一种减毒活的埃尔托型霍乱弧菌疫苗株Peru2,使其从质粒[Peru2 (pETR5.1)]或染色体插入片段(ETR3)表达SREHP-12-CTB融合蛋白至上清液中。将载体菌株口服给予无菌小鼠,随后将其饲养在非无菌条件下;小鼠接受一次(第0天)或两次(第0天和第14天)接种。未给予免疫佐剂或霍乱全毒素。接受两次Peru2(pETR5.1)接种的小鼠具有最明显的抗阿米巴全身和黏膜免疫反应。接受ETR3菌株一次或两次口服接种的小鼠也诱导出了不太明显但显著的抗SREHP血清免疫球蛋白G抗体反应。通过血清杀弧菌抗体的诱导以及血清和黏膜抗CTB抗体反应的检测,也诱导出了抗霍乱弧菌反应。这些结果表明,霍乱弧菌载体菌株可以成功地作为SREHP-12-CTB融合蛋白的递送载体,以诱导黏膜和全身抗阿米巴及抗霍乱弧菌免疫反应。这些反应的强度与载体菌株产生的SREHP-12-CTB的量成正比。